What to Expect Week by Week
Semaglutide (Ozempic/Wegovy) produces significant, sustained weight loss in clinical trials — averaging 15% of body weight over 68 weeks in the STEP 1 trial. Here is what the research shows about typical results at each stage.
Source: STEP 1 Trial (Wegovy, 2.4 mg) | Duration: 68 weeks | Individual results vary.
Important: Results shown are from clinical trials and represent averages. Individual results vary significantly based on dose, diet, exercise, metabolic health, and adherence. This page is for informational purposes only. Consult a qualified healthcare professional before use.
Starting dose: 0.25 mg/week. Most users experience reduced appetite within the first week. Weight loss during this phase is typically 1–3 lbs as the body adjusts. GI side effects (nausea, reduced appetite) are most prominent during this phase.
Dose increases to 0.5 mg/week. Average weight loss of 3–5% of body weight by week 8 in clinical trials. Appetite suppression becomes more pronounced. GI side effects typically begin to improve.
Dose escalation continues (0.5 mg → 1.0 mg → 1.7 mg). Most users experience the fastest rate of weight loss during this phase. Average cumulative loss of 8–10% of body weight by week 20.
Maintenance dose of 2.4 mg/week reached. Weight loss continues but at a slower rate. Average cumulative loss of 12–14% by week 52. Body composition improvements (reduced visceral fat) become measurable.
Most users reach their maximum weight loss by week 52–60. Average total loss of 14.9% at week 68 in the STEP 1 trial. Maintaining the dose is required to sustain results — weight regain occurs after discontinuation.
Clinical trials pair semaglutide with a reduced-calorie diet. Users who maintain dietary discipline consistently achieve better outcomes.
The STEP 1 trial included lifestyle counseling. Adding resistance exercise helps preserve lean muscle mass during weight loss.
Consistent weekly dosing is critical. Missing doses or premature dose reduction significantly reduces outcomes.
Patients with higher baseline BMI tend to lose more absolute weight but similar percentages.
Patients with type 2 diabetes tend to lose slightly less weight than non-diabetic patients on the same dose.
Clinical trials show an average weight loss of 14.9% of body weight over 68 weeks with semaglutide 2.4 mg (Wegovy). Individual results vary based on diet, exercise, and metabolic factors.
Most users notice reduced appetite within the first 1–2 weeks. Measurable weight loss (3–5%) typically occurs within 4–8 weeks. Maximum results are typically achieved at 52–68 weeks.
Semaglutide produces weight loss even without significant lifestyle changes, but clinical trials pair it with reduced-calorie diet and exercise counseling. Combined approaches produce better outcomes.
Clinical data shows that most patients regain approximately two-thirds of their lost weight within one year of stopping semaglutide. The drug appears to require ongoing use to maintain results.
Head-to-head data from the SURMOUNT-5 trial shows tirzepatide produces approximately 20% greater weight loss than semaglutide at comparable doses. Both are effective, but tirzepatide has a slight efficacy advantage.
Purgo Labs provides HPLC-verified, third-party tested Semaglutide for legitimate research purposes. Every batch includes a certificate of analysis.
Shop Semaglutide at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.